Atropos Therapeutics is developing senosuppressors, a class of drugs that slow down the rate at which senescent cells form. The company points out that these are not the same as senolytics, which kill senescent cells. Currently, Atropos is in an early preclinical stage, identifying candidates through phenotypic screening with its proprietary platform, First ATRX-based Therapeutics to Elucidate Senescence (FATES).
The company is also developing senostimulators, a class of drugs that encourage cells to become senescent, as a potential therapy against cancer.
Atropos is currently seeking $1 million in seed funding to identify an initial indication with which to proceed to preclinical studies, among other activities.